General Comments / Chat, page-7704

The trial design of EMD AML has been explained as due to the positive response to Zantrene and the better potential recruitment given no other trials were focused on this area noting that AML trial space is overcrowded/competitive. Initially, I believe, management were advised recruitment should be reasonable by their trial partners but it has not turned out that way particularly in Australia due to the issue of scans not being considered by clinicians (even though Race offered to pay). The trial design seemed quite well thought out for the circumstances. I do have some questions around old formula vs new formula Zantrene and the rule it has played, if any, and whether it makes sense to continue if close at hand. Might get to DCB on that one....